AIM Vaccine (HKG:6660) said its rabies vaccine received China's National Medical Products Administration (NMPA) approval for holding clinical trials, according to a Friday filing with the Hong Kong bourse.
The human diploid rabies vaccine uses human diploid cells instead of Vero cells, which are homologous to humans and have a natural safety advantage compared with the traditional Vero cell rabies vaccines, the filing added.
The company's shares were down by 17% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.